질병 치료용 생물학적 제제 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 프로세스별, 전개별, 디바이스별(-2035년)

Biologics for Disease Treatment Market is anticipated to expand from $561.0 billion in 2024 to $1403.1 billion by 2034, growing at a CAGR of approximately 11.6%. The Biologics for Disease Treatment Market encompasses therapeutic products derived from living organisms, including monoclonal antibodies, vaccines, and cell therapies. These biologics target complex diseases such as cancer, autoimmune disorders, and infectious diseases. The market is driven by advancements in biotechnology, personalized medicine, and regulatory approvals, emphasizing efficacy and safety. Increasing prevalence of chronic diseases and demand for innovative treatments propel growth, with significant investment in research and development.

The Biologics for Disease Treatment Market is experiencing robust growth, driven by advancements in biotechnology and personalized medicine. The monoclonal antibodies segment stands out as the top-performing category, widely adopted for their specificity and efficacy in targeting diseases. Within this segment, oncology applications dominate, reflecting the urgent need for innovative cancer therapies. Following closely, the vaccines segment emerges as the second-highest performer, spurred by increasing emphasis on preventive healthcare and immunization programs. The rise in infectious diseases and the development of novel vaccine platforms contribute to this growth. The cell therapy sub-segment also shows promising potential, particularly in regenerative medicine and chronic disease management. The market is further bolstered by strategic partnerships and collaborations between biotech firms and pharmaceutical giants, fostering innovation and accelerating product development. Regulatory support and advancements in manufacturing technologies enhance market dynamics, ensuring a steady supply of high-quality biologics.

In the Biologics for Disease Treatment Market, market share is dominated by a few key players, with pricing strategies reflecting the premium nature of biologics. The market is witnessing a surge in new product launches, driven by innovation and technological advancements. Companies are focusing on developing biologics that target specific diseases, enhancing their therapeutic efficacy. Pricing remains competitive, with manufacturers balancing cost-effectiveness and profitability. The market is characterized by strategic partnerships and collaborations, facilitating the introduction of novel biologics. Competition benchmarking reveals that established pharmaceutical giants maintain a strong foothold, yet emerging biotech firms are gaining traction through niche offerings. Regulatory influences are significant, with stringent guidelines impacting market dynamics. The FDA and EMA play pivotal roles in shaping the approval process, affecting the speed and success of product launches. Market data indicates a trend towards personalized medicine, with biologics tailored to individual patient profiles. The landscape is evolving, with regulatory frameworks adapting to accommodate innovative therapies, ensuring safety and efficacy while fostering market growth.

Geographical Overview:

The biologics for disease treatment market is witnessing substantial growth across various regions, each showcasing unique opportunities. North America remains a dominant force, driven by advanced healthcare infrastructure and significant investments in biologics research. The region's focus on innovative therapies and personalized medicine further bolsters its market position. Europe follows closely, benefiting from strong regulatory frameworks and a robust ecosystem for biologics development. The emphasis on sustainable healthcare solutions enhances Europe's market appeal. In the Asia Pacific, the market is expanding rapidly, propelled by rising healthcare expenditures and increasing prevalence of chronic diseases. Emerging economies like China and India are investing heavily in biologics manufacturing and research. Latin America and the Middle East & Africa are nascent markets with considerable potential. Brazil and Saudi Arabia are notable contributors, recognizing the importance of biologics in addressing unmet medical needs and driving healthcare advancements. These regions are poised for growth as they embrace innovative treatment solutions.

The biologics market for disease treatment is intricately influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea are bolstering their domestic biologics production capabilities to mitigate dependency on imports, while China accelerates innovation in biologics amid Western trade restrictions. Taiwan's pivotal role in biologics manufacturing is underscored by its geopolitical vulnerability, necessitating strategic alliances. The global biologics market is robust, driven by advances in personalized medicine and increasing prevalence of chronic diseases. By 2035, the market is anticipated to thrive on innovation and strategic regional partnerships. Concurrently, Middle East conflicts pose potential disruptions to energy supplies, affecting production costs and timelines globally, thereby underscoring the need for resilient and flexible supply chain strategies.

Key Trends and Drivers:

The biologics for disease treatment market is experiencing robust growth, driven by advancements in biotechnology and personalized medicine. Key trends include the surge in monoclonal antibodies and gene therapies, which are revolutionizing treatment options for chronic and rare diseases. The increasing prevalence of cancer, autoimmune disorders, and infectious diseases is propelling demand for biologics, offering targeted and effective therapeutic solutions. Moreover, regulatory support and expedited approval processes for biologics are enabling faster market entry, enhancing accessibility for patients. The growing investment in research and development by pharmaceutical companies is fostering innovation and expanding the biologics pipeline. Additionally, the rising adoption of biosimilars is contributing to market growth, providing cost-effective alternatives while maintaining therapeutic efficacy. The integration of artificial intelligence and machine learning in biologics development is optimizing drug discovery and development processes. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness of biologics is increasing. Companies focusing on strategic collaborations and partnerships are well-positioned to capitalize on these trends, ensuring sustained market expansion.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Deployment
• 2.9 Key Market Highlights by Device

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Monoclonal Antibodies
  • 4.1.2 Recombinant Proteins
  • 4.1.3 Cell Therapy
  • 4.1.4 Gene Therapy
  • 4.1.5 Vaccines
  • 4.1.6 Fusion Proteins
  • 4.1.7 Antibody-Drug Conjugates
  • 4.1.8 Biosimilars
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Therapeutic Proteins
  • 4.2.2 Peptide Therapeutics
  • 4.2.3 Enzymes
  • 4.2.4 Hormones
  • 4.2.5 Blood Factors
  • 4.2.6 Interferons
  • 4.2.7 Cytokines
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Manufacturing
  • 4.3.2 Research and Development
  • 4.3.3 Regulatory Support
  • 4.3.4 Clinical Trials
  • 4.3.5 Quality Assurance
  • 4.3.6 Supply Chain Management
  • 4.3.7 Bioprocessing
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Recombinant DNA Technology
  • 4.4.2 Hybridoma Technology
  • 4.4.3 Transgenic Technology
  • 4.4.4 CRISPR Technology
  • 4.4.5 Nanotechnology
  • 4.4.6 Bioprinting
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Autoimmune Diseases
  • 4.5.3 Infectious Diseases
  • 4.5.4 Cardiovascular Diseases
  • 4.5.5 Neurological Disorders
  • 4.5.6 Metabolic Disorders
  • 4.5.7 Rare Diseases
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Clinics
  • 4.6.3 Research Institutes
  • 4.6.4 Biopharmaceutical Companies
  • 4.6.5 Contract Research Organizations
  • 4.6.6 Academic Institutions
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Upstream Processing
  • 4.7.2 Downstream Processing
  • 4.7.3 Formulation
  • 4.7.4 Fill and Finish
  • 4.7.5 Packaging
• 4.8 Market Size & Forecast by Deployment (2020-2035)
  • 4.8.1 In-house
  • 4.8.2 Outsourced
  • 4.8.3 Hybrid
• 4.9 Market Size & Forecast by Device (2020-2035)
  • 4.9.1 Bioreactors
  • 4.9.2 Centrifuges
  • 4.9.3 Chromatography Systems
  • 4.9.4 Filtration Systems

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Process
    • 5.2.1.8 Deployment
    • 5.2.1.9 Device
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Process
    • 5.2.2.8 Deployment
    • 5.2.2.9 Device
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Process
    • 5.2.3.8 Deployment
    • 5.2.3.9 Device
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Process
    • 5.3.1.8 Deployment
    • 5.3.1.9 Device
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Process
    • 5.3.2.8 Deployment
    • 5.3.2.9 Device
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Process
    • 5.3.3.8 Deployment
    • 5.3.3.9 Device
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Process
    • 5.4.1.8 Deployment
    • 5.4.1.9 Device
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Process
    • 5.4.2.8 Deployment
    • 5.4.2.9 Device
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Process
    • 5.4.3.8 Deployment
    • 5.4.3.9 Device
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Process
    • 5.4.4.8 Deployment
    • 5.4.4.9 Device
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Process
    • 5.4.5.8 Deployment
    • 5.4.5.9 Device
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Process
    • 5.4.6.8 Deployment
    • 5.4.6.9 Device
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Process
    • 5.4.7.8 Deployment
    • 5.4.7.9 Device
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Process
    • 5.5.1.8 Deployment
    • 5.5.1.9 Device
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Process
    • 5.5.2.8 Deployment
    • 5.5.2.9 Device
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Process
    • 5.5.3.8 Deployment
    • 5.5.3.9 Device
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Process
    • 5.5.4.8 Deployment
    • 5.5.4.9 Device
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Process
    • 5.5.5.8 Deployment
    • 5.5.5.9 Device
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Process
    • 5.5.6.8 Deployment
    • 5.5.6.9 Device
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Process
    • 5.6.1.8 Deployment
    • 5.6.1.9 Device
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Process
    • 5.6.2.8 Deployment
    • 5.6.2.9 Device
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Process
    • 5.6.3.8 Deployment
    • 5.6.3.9 Device
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Process
    • 5.6.4.8 Deployment
    • 5.6.4.9 Device
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Process
    • 5.6.5.8 Deployment
    • 5.6.5.9 Device

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Regeneron Pharmaceuticals
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Vertex Pharmaceuticals
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Sarepta Therapeutics
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Bio Marin Pharmaceutical
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Alnylam Pharmaceuticals
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Moderna
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Incyte
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Alexion Pharmaceuticals
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Biogen
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Gilead Sciences
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Amgen
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Illumina
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Jazz Pharmaceuticals
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Novavax
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Seagen
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Genmab
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Ipsen
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 UCB
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Ascendis Pharma
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 CRISPR Therapeutics
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us